ct-1500
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2021 (NCT05070702)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05070702 | Phase 1 | Oct 20, 2021 | Cascadian Therapeutics Inc., Neuroscience Trials Australia, Nucleus Network Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cascadian Therapeutics Inc. | For profit | 1 | 1 | 1 | 2021 |
| Neuroscience Trials Australia | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1